Citadel Advisors’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Citadel Advisors’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,580	Closed	-$456	–	15814
2024 Q4	$456	Sell	13,580 -4,825	-26%	-$194	﹤0.01%	14321
2024 Q3	$583	Buy	+18,405	New	+$1.07K	﹤0.01%	13992

Other funds holding SLXNW

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's SLXNW Position: Q1 2025 in Review

Citadel Advisors sold out of Silexion Therapeutics Warrant (SLXNW) in Q1 2025, closing a stake of 13,580 shares — an estimated $456 sold.

Citadel Advisors first reported a position in SLXNW in Q3 2024 and held it in 2 quarters. The position peaked at $583 in Q3 2024. 25 funds tracked by Wall St. Rank hold SLXNW as of Q1 2025.

Citadel Advisors reported no remaining Silexion Therapeutics Warrant position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 13,580 Silexion Therapeutics Warrant shares in Q1 2025, an estimated $456.
Citadel Advisors first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 2 quarters.
Citadel Advisors's Silexion Therapeutics Warrant position peaked at $583 in Q3 2024.
25 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.